Literature DB >> 23937153

Serum or breast milk immunoglobulins mask the self-reactivity of human natural IgG antibodies.

Iglika Djoumerska-Alexieva1, Iliyan Manoylov, Jordan D Dimitrov, Andrey Tchorbanov.   

Abstract

B cells producing IgG antibodies specific to a variety of self- or foreign antigens are a normal constituent of the immune system of all healthy individuals. These naturally occurring IgG antibodies are found in the serum, external secretions, and pooled human immunoglobulin preparations. They bind with low affinity to antigens, which can also be targets for pathologic autoantibodies. An enhancement of naturally occurring IgG autoantibody activity was observed after treatment of human IgG molecules with protein-destabilizing agents. We have investigated the interactions of human immunoglobulins that were obtained from serum or from breast milk of healthy individuals or IVIg with human liver antigens. Proteins from an individual serum or milk were isolated by two methods, one of which included exposure to low pH and the other did not. Purified serum, mucosal IgM, IgA, and the fraction containing immunoglobulin G F(ab')2 fragments each inhibited the binding of a single donor or pooled IgG to human liver antigens. Our study presents findings regarding the role of the breast milk or serum antibodies in blocking the self-reactivity of IgG antibodies. It supports the suggestion that not IVIg only, but also the pooled human IgM and IgA might possess a potent beneficial immunomodulatory activity in autoimmune patients.
© 2013 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  IgM and IgA; Mucosal IgG; autoreactivity; immunomodulation

Mesh:

Substances:

Year:  2013        PMID: 23937153     DOI: 10.1111/apm.12149

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  1 in total

1.  Lectin-based analysis of fucosylated glycoproteins of human skim milk during 47 days of lactation.

Authors:  Jolanta Lis-Kuberka; Iwona Kątnik-Prastowska; Marta Berghausen-Mazur; Magdalena Orczyk-Pawiłowicz
Journal:  Glycoconj J       Date:  2015-08-30       Impact factor: 2.916

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.